297 related articles for article (PubMed ID: 24782261)
1. Will there be a vaccine to prevent HCV infection?
Honegger JR; Zhou Y; Walker CM
Semin Liver Dis; 2014 Feb; 34(1):79-88. PubMed ID: 24782261
[TBL] [Abstract][Full Text] [Related]
2. Characterizing Hepatitis C Virus-Specific CD4
Hartnell F; Esposito I; Swadling L; Brown A; Phetsouphanh C; de Lara C; Gentile C; Turner B; Dorrell L; Capone S; Folgori A; Barnes E; Klenerman P
Hepatology; 2020 Nov; 72(5):1541-1555. PubMed ID: 32012325
[TBL] [Abstract][Full Text] [Related]
3. Novel adeno‑associated virus‑based genetic vaccines encoding hepatitis C virus E2 glycoprotein elicit humoral immune responses in mice.
Zhu F; Wang Y; Xu Z; Qu H; Zhang H; Niu L; Xue H; Jing D; He H
Mol Med Rep; 2019 Feb; 19(2):1016-1023. PubMed ID: 30569131
[TBL] [Abstract][Full Text] [Related]
4. Single-Dose Vaccination with a Hepatotropic Adeno-associated Virus Efficiently Localizes T Cell Immunity in the Liver with the Potential To Confer Rapid Protection against Hepatitis C Virus.
Mekonnen ZA; Grubor-Bauk B; English K; Leung P; Masavuli MG; Shrestha AC; Bertolino P; Bowen DG; Lloyd AR; Gowans EJ; Wijesundara DK
J Virol; 2019 Oct; 93(19):. PubMed ID: 31292249
[TBL] [Abstract][Full Text] [Related]
5. Persistent hepatitis C viral replication despite priming of functional CD8+ T cells by combined therapy with a vaccine and a direct-acting antiviral.
Callendret B; Eccleston HB; Satterfield W; Capone S; Folgori A; Cortese R; Nicosia A; Walker CM
Hepatology; 2016 May; 63(5):1442-54. PubMed ID: 26513111
[TBL] [Abstract][Full Text] [Related]
6. Hepatitis C virus: why do we need a vaccine to prevent a curable persistent infection?
Walker CM; Grakoui A
Curr Opin Immunol; 2015 Aug; 35():137-43. PubMed ID: 26241306
[TBL] [Abstract][Full Text] [Related]
7. Hepatitis C virus vaccine design: focus on the humoral immune response.
Sepulveda-Crespo D; Resino S; Martinez I
J Biomed Sci; 2020 Jul; 27(1):78. PubMed ID: 32631318
[TBL] [Abstract][Full Text] [Related]
8. Adenovirus-vectored T cell vaccine for hepacivirus shows reduced effectiveness against a CD8 T cell escape variant in rats.
Hartlage AS; Dravid P; Walker CM; Kapoor A
PLoS Pathog; 2021 Mar; 17(3):e1009391. PubMed ID: 33735321
[TBL] [Abstract][Full Text] [Related]
9. Induction of Genotype Cross-Reactive, Hepatitis C Virus-Specific, Cell-Mediated Immunity in DNA-Vaccinated Mice.
Wijesundara DK; Gummow J; Li Y; Yu W; Quah BJ; Ranasinghe C; Torresi J; Gowans EJ; Grubor-Bauk B
J Virol; 2018 Apr; 92(8):. PubMed ID: 29437963
[TBL] [Abstract][Full Text] [Related]
10. Hepatitis C Virus Vaccine Research: Time to Put Up or Shut Up.
Hartlage AS; Kapoor A
Viruses; 2021 Aug; 13(8):. PubMed ID: 34452460
[TBL] [Abstract][Full Text] [Related]
11. Chronic hepatitis C viral infection subverts vaccine-induced T-cell immunity in humans.
Kelly C; Swadling L; Capone S; Brown A; Richardson R; Halliday J; von Delft A; Oo Y; Mutimer D; Kurioka A; Hartnell F; Collier J; Ammendola V; Del Sorbo M; Grazioli F; Esposito ML; Di Marco S; Siani L; Traboni C; Hill AV; Colloca S; Nicosia A; Cortese R; Folgori A; Klenerman P; Barnes E
Hepatology; 2016 May; 63(5):1455-70. PubMed ID: 26474390
[TBL] [Abstract][Full Text] [Related]
12. Methods to Evaluate Novel Hepatitis C Virus Vaccines.
Ahlén G; Frelin L
Methods Mol Biol; 2016; 1403():221-44. PubMed ID: 27076133
[TBL] [Abstract][Full Text] [Related]
13. Immunogenicity of CIGB-230, a therapeutic DNA vaccine preparation, in HCV-chronically infected individuals in a Phase I clinical trial.
Alvarez-Lajonchere L; Shoukry NH; Grá B; Amador-Cañizares Y; Helle F; Bédard N; Guerra I; Drouin C; Dubuisson J; González-Horta EE; Martínez G; Marante J; Cinza Z; Castellanos M; Dueñas-Carrera S
J Viral Hepat; 2009 Mar; 16(3):156-67. PubMed ID: 19017255
[TBL] [Abstract][Full Text] [Related]
14. A T-cell HCV vaccine eliciting effective immunity against heterologous virus challenge in chimpanzees.
Folgori A; Capone S; Ruggeri L; Meola A; Sporeno E; Ercole BB; Pezzanera M; Tafi R; Arcuri M; Fattori E; Lahm A; Luzzago A; Vitelli A; Colloca S; Cortese R; Nicosia A
Nat Med; 2006 Feb; 12(2):190-7. PubMed ID: 16462801
[TBL] [Abstract][Full Text] [Related]
15. IFNL3-adjuvanted HCV DNA vaccine reduces regulatory T cell frequency and increases virus-specific T cell responses.
Han JW; Sung PS; Hong SH; Lee H; Koh JY; Lee H; White S; Maslow JN; Weiner DB; Park SH; Jeong M; Heo J; Ahn SH; Shin EC
J Hepatol; 2020 Jul; 73(1):72-83. PubMed ID: 32088322
[TBL] [Abstract][Full Text] [Related]
16. Vaccination to prevent T cell subversion can protect against persistent hepacivirus infection.
Hartlage AS; Murthy S; Kumar A; Trivedi S; Dravid P; Sharma H; Walker CM; Kapoor A
Nat Commun; 2019 Mar; 10(1):1113. PubMed ID: 30846697
[TBL] [Abstract][Full Text] [Related]
17. Modeling indicates efficient vaccine-based interventions for the elimination of hepatitis C virus among persons who inject drugs in metropolitan Chicago.
Echevarria D; Gutfraind A; Boodram B; Layden J; Ozik J; Page K; Cotler SJ; Major M; Dahari H
Vaccine; 2019 May; 37(19):2608-2616. PubMed ID: 30962092
[TBL] [Abstract][Full Text] [Related]
18. A Multiantigenic DNA Vaccine That Induces Broad Hepatitis C Virus-Specific T-Cell Responses in Mice.
Gummow J; Li Y; Yu W; Garrod T; Wijesundara D; Brennan AJ; Mullick R; Voskoboinik I; Grubor-Bauk B; Gowans EJ
J Virol; 2015 Aug; 89(15):7991-8002. PubMed ID: 26018154
[TBL] [Abstract][Full Text] [Related]
19. Neutralising antibody, CTL and dendritic cell responses to hepatitis C virus: a preventative vaccine strategy.
Torresi J; Bharadwaj M; Jackson DC; Gowans EJ
Curr Drug Targets; 2004 Jan; 5(1):41-56. PubMed ID: 14738217
[TBL] [Abstract][Full Text] [Related]
20. Advances in hepatitis C virus vaccines, Part one: Advances in basic knowledge for hepatitis C virus vaccine design.
Roohvand F; Kossari N
Expert Opin Ther Pat; 2011 Dec; 21(12):1811-30. PubMed ID: 22022980
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
